Randomized phase 2 trial of bortezomib-dexamethasone (VD) versus VD plus cyclophosphamide or lenalidomide in myeloma patients achieving stable disease after 4 cycles of VD as second-line treatment
Randomized phase 2 trial of bortezomib-dexamethasone (VD) versus VD plus cyclophosphamide or lenalidomide in myeloma patients achieving stable disease after 4 cycles of VD as second-line treatment
Languages of Item:
English
Abstract:
Empty abstract
Publication year:
2010
Authors:
Dimopoulos, M Roddie, H Beksac, M Benboubker, L de la Rubia, J Casado, L Allietta, N Angermund, R Facon, T
